1stOncology™: Cancer Intelligence Service – Page 7336 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

On February 10, 2022 Ascendis Pharma A/S (Nasdaq: ASND) reported that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference (Press release, Ascendis Pharma, FEB 10, 2022, View Source [SID1234607972]). Company executives will participate in a virtual fireside chat hosted by SVB Leerink.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details

Event 11th Annual SVB Leerink Global Healthcare Conference
Location Virtual
Date Wednesday, February 16, 2022
Time 3:00-3:30 p.m. Eastern Time
A live webcast of the event will be available on the Investors and News section of the Ascendis Pharma website at View Source A webcast replay will be available on the site shortly after conclusion of the event and will stay available for 30 days.

Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

On February 10, 2022 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that it will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets (Press release, Clovis Oncology, FEB 10, 2022, View Source [SID1234607971]). Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company’s results in greater detail.

The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.

Dial-in numbers for the conference call are as follows: US participants 888.440.4615, International participants 646.960.0682, conference ID: 2259685.

ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

On February 10, 2022 ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results (Press release, ImmunoGen, FEB 10, 2022, View Source [SID1234607970]). Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION
To access the live call by phone, dial (877) 621-5803; the conference ID is 5566069. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022

On February 10, 2022 Palatin Technologies, Inc. (NYSE American: PTN) reported that it will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022, before the open of the U.S. financial markets (Press release, Palatin Technologies, FEB 10, 2022, View Source [SID1234607969]).

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2022, at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development.

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin’s website at View Source

SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement

On February 10, 2022 SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, reported the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer (Press release, Shine Medical Technologies, FEB 10, 2022, View Source [SID1234607968]).

SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the US market.

"There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers," said Greg Piefer, SHINE’s founder and CEO. "Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver Lu-177 for highly precise treatments that produce little damage in the tissue around treatment sites."

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. Several Lu-177 therapies are currently being developed to treat various forms of cancer and may provide alternative treatment options for patients where other therapeutic solutions have proven insufficient.

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, "SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the US market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage."